Search: onr:"swepub:oai:DiVA.org:oru-94785" >
The Cost-Effectiven...
-
Jendle, Johan,1963-Örebro universitet,Institutionen för medicinska vetenskaper
(author)
The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes : a Health Economic Analysis in Sweden
- Article/chapterEnglish2021
Publisher, publication year, extent ...
-
2021-10-01
-
Springer,2021
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:oru-94785
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-94785URI
-
https://doi.org/10.1007/s13300-021-01157-0DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding agency:Medtronic International Trading Sàrl, Geneva, Switzerland
-
INTRODUCTION: Swedish National Diabetes Registry data show a correlation of improved glycemic control in people with type 1 diabetes (T1D) with increased use of diabetes technologies over the past 25 years. However, novel technologies are often associated with a high initial outlay. The aim of the present study was to evaluate the long-term cost-effectiveness of the advanced hybrid closed-loop (AHCL) MiniMed 780G system versus intermittently scanned continuous glucose monitoring (isCGM) plus self-injection of multiple daily insulin (MDI) or continuous subcutaneous insulin infusion (CSII) in people with T1D in Sweden.METHODS: Outcomes were projected over patients' lifetimes using the IQVIA CORE Diabetes Model (v9.0). Clinical data, including changes in glycated hemoglobin (HbA1c) and hypoglycemia rates, were sourced from observational studies and a randomized crossover trial. Modeled patients were assumed to receive the treatments for their lifetimes, with HbA1c kept constant following the application of treatment effects. Costs were accounted from a societal perspective and expressed in Swedish krona (SEK). Utilities and days off work estimates were taken from published sources.RESULTS: The MiniMed 780G system was associated with an improvement in life expectancy of 0.16 years and an improvement in quality-adjusted life expectancy of 1.95 quality-adjusted life years (QALYs) versus isCGM plus MDI or CSII. These clinical benefits were due to a reduced incidence and a delayed time to onset of diabetes-related complications. Combined costs were estimated to be SEK 727,408 (EUR 72,741) higher with MiniMed 780G, with treatment costs partially offset by direct cost savings from the avoidance of diabetes-related complications and indirect cost savings from the avoidance of lost workplace productivity. The MiniMed 780G system was associated with an incremental cost-effectiveness ratio of SEK 373,700 per QALY gained.CONCLUSIONS: Based on a willingness-to-pay threshold of SEK 500,000 per QALY gained, the MiniMed 780G system was projected to be cost-effective versus isCGM plus MDI or CSII for the treatment of T1D in Sweden.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Buompensiere, M. I.Medtronic International Trading Sàrl, Tolochenaz, Switzerland
(author)
-
Holm, A. L.Medtronic Denmark, Copenhagen, Denmark
(author)
-
de Portu, S.Medtronic International Trading Sàrl, Tolochenaz, Switzerland
(author)
-
Malkin, S. J. P.Ossian Health Economics and Communications, Basel, Switzerland
(author)
-
Cohen, O.Medtronic International Trading Sàrl, Tolochenaz, Switzerland
(author)
-
Örebro universitetInstitutionen för medicinska vetenskaper
(creator_code:org_t)
Related titles
-
In:Diabetes Therapy: Springer12:11, s. 2977-29911869-69531869-6961
Internet link
Find in a library
To the university's database